MCH Group | Ad hoc announcement pursuant to Art. 53 LR | New art fair in Paris
Art Basel selected to stage new contemporary art fair in Paris
MCH Group Ltd., based in Basel/Switzerland, announces that Art Basel has been awarded a seven-year contract to stage a new contemporary art fair in Paris, following a public competition initiated by the "Réunion des musées nationaux – Grand Palais" in December last year.
Launching in October 2022, the new art event will take place at the temporary venue "Grand Palais Éphémère" until the restoration of the "Grand Palais" is completed in 2024. Together with the "Réunion des musées nationaux – Grand Palais", Art Basel will strive to create a fair truly rooted in the twenty-first century that radiates throughout the city and is firmly embedded in Paris and its cultural and creative industries.
MCH Group intends to establish a new French legal entity and employ a dedicated team on the ground. It is planed to develop an identity and a brand specific to the Parisian fair.
"City Activation is a key element in our strategy," says Beat Zwahlen, CEO of MCH Group. "We’ve demonstrated before that we’re able to successfully build events in other locations that create tremendous economic impact." Andrea Zappia, Chairman of the Board of Directors of MCH Group, underlines: "Basel is and will remain our home base, and we are 100% committed to our existing Art Basel events in Basel, Miami Beach and Hong-Kong. Paris has become a major destination for the creative world and we welcome this opportunity to build something truly original for the French art market and culture industries."
Head of Corporate Communications
+41 58 206 22 43
+ 41 58 206 22 52
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Maha Energy: Borrningen av Tie-5 slutförd efter att 240 meter produktiv reservoar genomborrats28.5.2022 23:30:00 CEST | Pressemelding
Maha Energy AB (publ) ("Maha" eller "Bolaget") meddelar att horisontal-borrningen av Tie-5 i Brasilien nu är klar. Slutligt djup för sex tums hålet nåddes den 3 maj och ett 4-1/2 tums produktionsrör har nu sänkts ner och säkrats i brunnen. Längden på horisontalhålet reducerades i slutskedet på grund av försämrade borrhålsförhållanden. Totalt penetrerades 240 meter av produktiv Agua Grande (AG) reservoar med hjälp av nedsänkta elektriska loggningsverktyg. Den horisontella sektionen kommer nu att stimuleras och saneras innan den sätts i produktion. Borrningen av Tie-5 nådde ett djup om 2 548 meter den 3 maj 2022. Totalt har 240 meter (netto) av AG-sand exponerats och ett 4-1/2 tums perforerat produktionsrör har nu sänkts och säkrats i hålet. Det kan jämföras med 14 meter (netto) AG-reservoar som exponerades i den vertikala brunnen Tie-4. Innan Tie-5 sätts i produktion kommer brunnen att genomgå en rad stimulerings- och saneringsoperationer för att rensa horisontalhålet från borrslam. Jon
Maha Energy: Tie-5 reaches Total Depth (TD) with 240 m of net reservoir penetrated28.5.2022 23:30:00 CEST | Press release
Maha Energy AB (publ) (“Maha” or the “Company”) is pleased to announce that drilling of the Tie-5 horizontal production well is now complete. TD of the 6-1/8” horizontal hole was reached on 3 May and a 4-1/2” completion liner has now been run. The length of the horizontal leg was reduced due to deteriorating hole conditions. A total of 240 m. of net Agua Grande (AG) sand has been logged using measurement while drilling tools and the horizontal section will now be stimulated and cleaned up before being placed on production. Drilling of the Tie-5 horizontal production reached a measured depth of 2,548 m on 3 May, 2022. A total of 240 m of net AG sand has been drilled and a 4-1/2” pre-perforated production liner has now been run in the hole. The exposed length of sand in Tie-5 should be compared with the 14 m. of net sand penetrated in Tie-4. Prior to the well being placed on production, the well will undergo a series of stimulation and clean out operations to enhance production. Jonas Li
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed28.5.2022 12:01:09 CEST | Press release
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed Frontline Ltd. (“Frontline” or the "Company") (NYSE: FRO – OSE: FRO) announces that it has agreed to acquire a total of 5,955,705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (“Euronav”) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline. Frontline will issue a total of 8,337,986 new shares as a result of these transactions, equivalent to an exchange ratio of 1.4. Frontline will be entitled to the declared USD 0,06 dividend to be paid by Euronav on the acquired shares on 8 June 2022. Settlement is expected to take place on or about 1 June 2022 by delivery of existing shares through a share lending arrangement with Frontline's main shareholder Hemen Holding Ltd. Following completion of the issue of the new Frontline shares, F
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma28.5.2022 00:58:29 CEST | Press release
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1 Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indicati
ObsEva Announces Corporate Updates27.5.2022 22:01:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Am